Opioid receptor blockade prevents exercise-associated autonomic failure in humans

Sofiya Milman, James Leu, Harry Shamoon, Septimiu Vele, Ilan Gabriely

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hypoglycemia and exercise both induce the release of β-endorphin, which plays an important role in the modulation of the autonomic response during subsequent events. Because opioid receptor (OR) blockade during antecedent hypoglycemia has been shown to prevent hypoglycemia-associated autonomic failure, we hypothesized that OR blockade during exercise would prevent exercise-associated autonomic failure (EAAF). We studied 8 healthy subjects on 2 consecutive days, each of whom participated in three different studies in random order. The protocol on day 1 involved one of the following: 1) two 90-min hyperinsulinemiceuglycemic clamps plus naloxone infusion (control); 2) two 90-min hyperinsulinemic-euglycemic clamps with exercise at 60% VO 2max, plus naloxone infusion (N+); or 3) same protocol as in the N+ group, but with saline infusion only (N-). On day 2, all were studied with stepped hyperinsulinemic-hypoglycemic clamps, using hormone concentrations and glucose turnover as indicators of hypoglycemia counterregulation. Compared with control, N- studies resulted in significantly blunted epinephrine and norepinephrine responses to subsequent hypoglycemia. Conversely, the N+ group exhibited unimpaired hypoglycemia counterregulation, characterized by appropriate increases in epinephrine, norepinephrine, and endogenous glucose production. Thus, OR blockade with naloxone during antecedent exercise prevents the development of acute EAAF by improving the catecholamine responses and by restoring endogenous glucose production.

Original languageEnglish (US)
Pages (from-to)1609-1615
Number of pages7
JournalDiabetes
Volume61
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Opioid Receptors
Hypoglycemia
Exercise
Naloxone
Glucose
Epinephrine
Norepinephrine
Endorphins
Glucose Clamp Technique
Hypoglycemic Agents
Catecholamines
Healthy Volunteers
Hormones

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Opioid receptor blockade prevents exercise-associated autonomic failure in humans. / Milman, Sofiya; Leu, James; Shamoon, Harry; Vele, Septimiu; Gabriely, Ilan.

In: Diabetes, Vol. 61, No. 6, 06.2012, p. 1609-1615.

Research output: Contribution to journalArticle

Milman, Sofiya ; Leu, James ; Shamoon, Harry ; Vele, Septimiu ; Gabriely, Ilan. / Opioid receptor blockade prevents exercise-associated autonomic failure in humans. In: Diabetes. 2012 ; Vol. 61, No. 6. pp. 1609-1615.
@article{b687e452fe8449c3b501407d2a520f03,
title = "Opioid receptor blockade prevents exercise-associated autonomic failure in humans",
abstract = "Hypoglycemia and exercise both induce the release of β-endorphin, which plays an important role in the modulation of the autonomic response during subsequent events. Because opioid receptor (OR) blockade during antecedent hypoglycemia has been shown to prevent hypoglycemia-associated autonomic failure, we hypothesized that OR blockade during exercise would prevent exercise-associated autonomic failure (EAAF). We studied 8 healthy subjects on 2 consecutive days, each of whom participated in three different studies in random order. The protocol on day 1 involved one of the following: 1) two 90-min hyperinsulinemiceuglycemic clamps plus naloxone infusion (control); 2) two 90-min hyperinsulinemic-euglycemic clamps with exercise at 60{\%} VO 2max, plus naloxone infusion (N+); or 3) same protocol as in the N+ group, but with saline infusion only (N-). On day 2, all were studied with stepped hyperinsulinemic-hypoglycemic clamps, using hormone concentrations and glucose turnover as indicators of hypoglycemia counterregulation. Compared with control, N- studies resulted in significantly blunted epinephrine and norepinephrine responses to subsequent hypoglycemia. Conversely, the N+ group exhibited unimpaired hypoglycemia counterregulation, characterized by appropriate increases in epinephrine, norepinephrine, and endogenous glucose production. Thus, OR blockade with naloxone during antecedent exercise prevents the development of acute EAAF by improving the catecholamine responses and by restoring endogenous glucose production.",
author = "Sofiya Milman and James Leu and Harry Shamoon and Septimiu Vele and Ilan Gabriely",
year = "2012",
month = "6",
doi = "10.2337/db11-1622",
language = "English (US)",
volume = "61",
pages = "1609--1615",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - Opioid receptor blockade prevents exercise-associated autonomic failure in humans

AU - Milman, Sofiya

AU - Leu, James

AU - Shamoon, Harry

AU - Vele, Septimiu

AU - Gabriely, Ilan

PY - 2012/6

Y1 - 2012/6

N2 - Hypoglycemia and exercise both induce the release of β-endorphin, which plays an important role in the modulation of the autonomic response during subsequent events. Because opioid receptor (OR) blockade during antecedent hypoglycemia has been shown to prevent hypoglycemia-associated autonomic failure, we hypothesized that OR blockade during exercise would prevent exercise-associated autonomic failure (EAAF). We studied 8 healthy subjects on 2 consecutive days, each of whom participated in three different studies in random order. The protocol on day 1 involved one of the following: 1) two 90-min hyperinsulinemiceuglycemic clamps plus naloxone infusion (control); 2) two 90-min hyperinsulinemic-euglycemic clamps with exercise at 60% VO 2max, plus naloxone infusion (N+); or 3) same protocol as in the N+ group, but with saline infusion only (N-). On day 2, all were studied with stepped hyperinsulinemic-hypoglycemic clamps, using hormone concentrations and glucose turnover as indicators of hypoglycemia counterregulation. Compared with control, N- studies resulted in significantly blunted epinephrine and norepinephrine responses to subsequent hypoglycemia. Conversely, the N+ group exhibited unimpaired hypoglycemia counterregulation, characterized by appropriate increases in epinephrine, norepinephrine, and endogenous glucose production. Thus, OR blockade with naloxone during antecedent exercise prevents the development of acute EAAF by improving the catecholamine responses and by restoring endogenous glucose production.

AB - Hypoglycemia and exercise both induce the release of β-endorphin, which plays an important role in the modulation of the autonomic response during subsequent events. Because opioid receptor (OR) blockade during antecedent hypoglycemia has been shown to prevent hypoglycemia-associated autonomic failure, we hypothesized that OR blockade during exercise would prevent exercise-associated autonomic failure (EAAF). We studied 8 healthy subjects on 2 consecutive days, each of whom participated in three different studies in random order. The protocol on day 1 involved one of the following: 1) two 90-min hyperinsulinemiceuglycemic clamps plus naloxone infusion (control); 2) two 90-min hyperinsulinemic-euglycemic clamps with exercise at 60% VO 2max, plus naloxone infusion (N+); or 3) same protocol as in the N+ group, but with saline infusion only (N-). On day 2, all were studied with stepped hyperinsulinemic-hypoglycemic clamps, using hormone concentrations and glucose turnover as indicators of hypoglycemia counterregulation. Compared with control, N- studies resulted in significantly blunted epinephrine and norepinephrine responses to subsequent hypoglycemia. Conversely, the N+ group exhibited unimpaired hypoglycemia counterregulation, characterized by appropriate increases in epinephrine, norepinephrine, and endogenous glucose production. Thus, OR blockade with naloxone during antecedent exercise prevents the development of acute EAAF by improving the catecholamine responses and by restoring endogenous glucose production.

UR - http://www.scopus.com/inward/record.url?scp=84861866236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861866236&partnerID=8YFLogxK

U2 - 10.2337/db11-1622

DO - 10.2337/db11-1622

M3 - Article

VL - 61

SP - 1609

EP - 1615

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 6

ER -